var data={"title":"Ertapenem: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ertapenem: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6127?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ertapenem-drug-information\" class=\"drug drug_general\">see &quot;Ertapenem: Drug information&quot;</a> and <a href=\"topic.htm?path=ertapenem-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ertapenem: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166533\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>INVanz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166534\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Invanz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047189\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Carbapenem</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047183\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ertapenem-drug-information\" class=\"drug drug_general\">see &quot;Ertapenem: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> IV therapy may be administered for up to 14 days; IM for up to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children (<i>Red Book</i> [AAP] 2015): Severe infections: IM, IV: 15 mg/kg/dose twice daily; maximum single dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IM, IV: 1,000 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection, complicated:</b> <b>Note:</b> IDSA guidelines recommend a treatment duration of 4 to 7 days (provided source controlled) for community-acquired, mild to moderate infections (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;3 months: IM, IV: 15 mg/kg/dose twice daily (<i>Red Book</i> [AAP] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months and Children: IM, IV: 15 mg/kg/dose twice daily for 5 to 14 days; maximum single dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IM, IV: 1,000 mg once daily for 5 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic infections, acute:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;3 months: IM, IV: 15 mg/kg/dose twice daily (<i>Red Book</i> [AAP] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months and Children: IM, IV: 15 mg/kg/dose twice daily for 3 to 10 days; maximum single dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IM, IV: 1,000 mg once daily for 3 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired:</b> <b>Note:</b> Duration includes possible switch to appropriate oral step-down therapy after at least 3 days of parenteral treatment, once clinical improvement demonstrated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;3 months: IM, IV: 15 mg/kg/dose twice daily (<i>Red Book</i> [AAP] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months and Children: IM, IV: 15 mg/kg/dose twice daily for 10 to 14 days; maximum single dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IM, IV: 1,000 mg once daily for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections, complicated or necrotizing:</b> <b>Note</b>: For complicated infection, continue therapy for 7 to 14 days. For necrotizing infection, use in combination with an agent effective against MRSA (eg, vancomycin, linezolid, daptomycin) for empiric therapy of polymicrobial (mixed) infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;3 months: IM, IV: 15 mg/kg/dose twice daily (<i>Red Book</i> [AAP] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months and Children: IM, IV: 15 mg/kg/dose twice daily; maximum single dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IM, IV: 1,000 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis:</b> Children and Adolescents: IV: 15 mg/kg 60 minutes before procedure; maximum dose: 1,000 mg (Bratzler 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urinary tract infections (including pyelonephritis):</b> <b>Note:</b> Duration includes possible switch to appropriate oral therapy after at least 3 days of parenteral treatment, once clinical improvement demonstrated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;3 months: IM, IV: 15 mg/kg/dose twice daily (<i>Red Book</i> [AAP] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months and Children: IM, IV: 15 mg/kg/dose twice daily for 10 to 14 days; maximum single dose: 500 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IM, IV: 1,000 mg once daily for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection:</b> IM, IV: 1,000 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis of surgical site infection following colorectal surgery:</b> IV: Single 1,000 mg dose administered 1 hour prior to surgical procedure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute/1.73 m<sup>2</sup>: 500 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous Ambulatory Peritoneal Dialysis (CAPD): 500 mg daily (Cardone 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: ~30% removed by hemodialysis (Curran 2003). If daily dose is given within 6 hours prior to hemodialysis, a supplementary dose of 150 mg should be given following hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166510\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INVanz: 1 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INVanz: 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166496\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047192\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IM: Administer deep into a large muscle mass such as the gluteus maximus or lateral part of the thigh. Avoid injection into a blood vessel. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intermittent IV infusion: Infuse over 30 minutes. Do not coinfuse with other medications. <b>Do not infuse with dextrose-containing solutions.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166528\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to reconstitution, store vials at &le;25&deg;C (77&deg;F). The reconstituted IM solution should be used within 1 hour after preparation. The reconstituted IV solution may be stored at room temperature (25&deg;C [77&deg;F]) and used within 6 hours, or stored for 24 hours under refrigeration (5&deg;C [41&deg;F]) and used within 4 hours after removal from refrigeration. Do not freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047191\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of moderate to severe, complicated intra-abdominal infections, acute pelvic infections, complicated skin and skin structure infections (including diabetic foot infections without osteomyelitis), community-acquired pneumonia, and complicated urinary tract infections (including pyelonephritis) caused by susceptible organisms  (FDA approved in ages &ge;3 months and adults); prophylaxis of surgical site infection following colorectal surgery (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166564\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ertapenem may be confused with doripenem, imipenem, meropenem</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INVanz may be confused with AVINza, IV vancomycin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166562\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest pain, edema, hypotension, phlebitis, thrombophlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Altered mental status (ie, agitation, confusion, disorientation, mental acuity decreased, somnolence, stupor), dizziness, headache, hypothermia (infants, children, and adolescents), insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaper rash (infants and children), genital rash (infants, children, and adolescents), pruritus, skin lesion (infants, children, and adolescents), skin rash </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, constipation, decreased appetite (infants, children, and adolescents), diarrhea, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Erythrocyturia, vaginitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, decreased neutrophils, eosinophilia, leukocyturia, leukopenia, thrombocythemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum alkaline, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Herpes simplex infection (infants, children, and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Infused vein complication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (infants, children, and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Otic infection (infants, children, and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough, dyspnea, nasopharyngitis (infants, children, and adolescents), rhinitis (infants, children, and adolescents), rhinorrhea (infants, children, and adolescents), upper respiratory tract infection (infants, children, and adolescents), wheezing (infants, children, and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Anaphylactoid reaction, anaphylaxis, anuria, asthma, asystole, atrial fibrillation, bradycardia, bronchoconstriction, cardiac arrest, cardiac arrhythmia, cardiac failure, cholelithiasis, <i>Clostridium difficile</i> associated diarrhea, delirium, DRESS syndrome, extravasation, gastrointestinal hemorrhage, gout, heart murmur, hemoptysis, hyperglycemia, hyperkalemia, hypertension, hypoxemia, impaired consciousness, intestinal obstruction, jaundice, oral candidiasis, oliguria, pancreatitis, pleural effusion, prolonged prothrombin time, renal insufficiency, seizure, septicemia, septic shock, subdural hematoma, tachycardia, thrombocytopenia, tissue necrosis, ventricular tachycardia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166515\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams; known hypersensitivity to local anesthetics of the amide type due to the use of lidocaine as a diluent (IM use only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166500\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylaxis/hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, have been reported (some without a history of previous allergic reactions to beta-lactams).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate-to-severe renal dysfunction. Increased seizure risk has been reported in patients with renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Valproic acid and derivatives:  Carbapenems, including ertapenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibiotics with divalproex sodium/valproic acid is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medication. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Lower doses (based upon renal function) are often required in the elderly. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> &bull; IM administration: Doses for IM administration are mixed with lidocaine; consult Lidocaine (Systemic) information for associated Warnings/Precautions. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299280\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166504\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12903&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Ertapenem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Ertapenem may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166506\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166516\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not observed in animal reproduction studies. Ertapenem is approved for the treatment of postpartum endomyometritis, septic abortion, and postsurgical infections. Information related to use during pregnancy has not been located. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047188\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic renal, hepatic, and hematologic function tests; neurological assessment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166499\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F166514\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Almost complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;3 months and Children: ~0.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents 13 to 17 years: ~0.16 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~0.12 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding (concentration dependent, primarily to albumin): 85% at 300 mcg/mL, 95% at &lt;100 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Non-CYP-mediated hydrolysis to inactive metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: IM: ~90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;3 months and Children: ~2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents and Adults: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: IM: ~2.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~80% as unchanged drug and metabolite); feces (~10%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047196\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium content: 1,000 mg ertapenem contains 6 mEq</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323133\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (INVanz Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $154.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (INVanz Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $162.10</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869380\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Etropen (BD);</li>\n      <li>Invanz (AE, AR, AT, AU, BB, BE, BG, BH, BO, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, KR, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, VE, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arguedas A, Cespedes J, Botet FA, et al, &quot;Safety and Tolerability of Ertapenem Versus Ceftriaxone in a Double-Blind Study Performed in Children With Complicated Urinary Tract Infection, Community-Acquired Pneumonia or Skin and Soft-Tissue Infection,&quot; <i> Int J Antimicrob Agents</i>, 2009, 33(2):163-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-pediatric-drug-information/abstract-text/18945594/pubmed\" target=\"_blank\" id=\"18945594\">18945594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardone KE, Grabe DW, Kulawy RW, et al. Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis.<i> Antimicrob Agents Chemother</i>. 2012;56(2):725-730.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-pediatric-drug-information/abstract-text/22083473/pubmed\" target=\"_blank\" id=\"22083473\">22083473</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Curran M, Simpson D, and Perry C, &ldquo;Ertapenem: A Review of Its Use in the Management of Bacterial Infections,&rdquo; <i>Drugs</i>, 2003, 63(17):1855-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-pediatric-drug-information/abstract-text/12921489/pubmed\" target=\"_blank\" id=\"12921489\">12921489</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invanz (ertapenem) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Invanz (ertapenem) [prescribing information]. Kirkland QC: Merck Canada Inc; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keating GM and Perry CM, &quot;Ertapenem: A Review of Its Use in the Treatment of Bacterial Infections,&quot; Drugs, 2005, 65(15):2151-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-pediatric-drug-information/abstract-text/16225376 /pubmed\" target=\"_blank\" id=\"16225376 \">16225376 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nix DE, Majumdar AK, and DiNubile MJ, &ldquo;Pharmacokinetics and Pharmacodynamics of Ertapenem: An Overview for Clinicians,&rdquo; <i>J Antimicrob Chemother</i>, 2004, 53(Suppl 2):ii23-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-pediatric-drug-information/abstract-text/15150180/pubmed\" target=\"_blank\" id=\"15150180\">15150180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(2):133-164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-pediatric-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ertapenem-pediatric-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12903 Version 95.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F166533\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F166534\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047189\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047183\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F166510\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F166496\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047192\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F166528\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047191\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F166564\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F166562\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F166515\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F166500\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299280\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F166504\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F166506\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F166516\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047188\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F166499\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F166514\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1047196\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323133\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869380\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12903|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ertapenem-drug-information\" class=\"drug drug_general\">Ertapenem: Drug information</a></li><li><a href=\"topic.htm?path=ertapenem-patient-drug-information\" class=\"drug drug_patient\">Ertapenem: Patient drug information</a></li></ul></div></div>","javascript":null}